Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$305.01M+208.47%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Matthijs Glastra
- Sector
- Technology
- Industry
- Hardware, Equipment & Parts
- Employees
- 3,000
- Beta
- 1.70
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 2.12
Financials
Revenue
$305.01M+208.5%Net Income
$2.02M-74.0%EBITDA
$42.08M+127.6%Free Cash Flow
$30.38M+297.4%EPS (diluted)
$0.05-77.3%Shares Outstanding (diluted)
42.71M+22.1%Operating Expenses
$83.96MCash & Debt
$149.22MReturn of Capital
$0.00Revenue by Segment (annual)
$980.60MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $980.60M | $53.83M | $1.47 |
| 2024 | $949.25M | $64.09M | $1.78 |
| 2023 | $881.66M | $72.88M | $2.03 |
| 2022 | $860.90M | $74.05M | $2.08 |
| 2021 | $706.79M | $50.33M | $1.42 |
| 2020 | $590.62M | $44.52M | $1.27 |
| 2019 | $626.10M | $40.77M | $1.16 |
| 2018 | $614.34M | $49.11M | $1.46 |
| 2017 | $521.29M | $60.05M | $1.14 |
| 2016 | $384.76M | $22.00M | $0.63 |
| 2015 | $373.60M | $35.62M | $1.03 |
| 2014 | $364.71M | $-24.25M | $-0.70 |
| 2013 | $341.61M | $7.31M | $0.21 |
| 2012 | $271.50M | $19.54M | $0.58 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from NOVT's reported EPS growth of 7.4% a year over 13 years.
- EPS in 5 years
- $2.10
- Implied price
- $37.84
- Return from $101.99
- -18.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $18.81 — -81.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.6% | -31.4% | -28.3% | -25.6% | -23.3% | -21.2% |
| 2.4% | -27.9% | -24.6% | -21.8% | -19.4% | -17.2% |
| 7.4% | -24.4% | -20.9% | -18.0% | -15.4% | -13.1% |
| 12.4% | -20.9% | -17.2% | -14.2% | -11.5% | -9.1% |
| 17.4% | -17.3% | -13.6% | -10.4% | -7.5% | -5.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-40.00%Social Signal Score
Mentions (19)
- News (RSS)seekingalpha·4d ago·Neutral
Novanta Inc. (NOVT) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow
View source ↗ - News (RSS)seekingalpha·8d ago·Neutral
Novanta Inc. (NOVT) Presents at Baird 2026 Global Industrial Conference 2026 - Slideshow
View source ↗ - News (RSS)fool·11d ago·Positive
Novanta (NOVT) Q3 2026 Earnings Call Transcript Record margins and medical momentum stand out, but a U.K. plant slowdown adds a clear headwind.
View source ↗ - Newsseekingalpha.com·12d ago·Positive
Novanta Inc. (NOVT) Q3 2026 Earnings Call Transcript Novanta Inc. ( NOVT ) Q3 2026 Earnings Call November 10, 2026 8:00 AM EST Company Participants Marcella Meditz Matthijs Glastra - CEO & Chairman of the Board John Lesica - Co-Chief Operating Officer of Medical Solutions Charles Ravetto - Co-Chief Operating Officer of Automation Enabling Technologies Robert Buckley - Chief Financial Officer Conference Call Participants Lee Jagoda - CJS Securities, Inc. Brian Drab - William Blair & Company L.L.C…
View source ↗ - Newsmarketbeat.com·12d ago·Neutral
What Novanta (NOVT) Said on Its Q3 Earnings Call Novanta NASDAQ: NOVT reported third-quarter revenue growth of 23% and its strongest organic growth in more than three years, as demand for robotics and advanced manufacturing products helped offset weakness in precision medicine. The company also completed its largest acquisition, Riverpoint Medical.
View source ↗ - Newsbusinesswire.com·12d ago·Neutral
Novanta to Present at the Jefferies Global Healthcare Conference on Wednesday, November 18, 2026 BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Chair & Chief Executive Officer, and John Lesica, Chief Operating Officer of Medical Solutions, are scheduled to present at the Jefferies Global Healthcare Conference on Wednesday, November 18, 2026, in Lo…
View source ↗ - Newszacks.com·13d ago·Positive
Novanta (NOVT) Q3 Earnings and Revenues Surpass Estimates Novanta (NOVT) came out with quarterly earnings of $1.05 per share, beating the Zacks Consensus Estimate of $0.97 per share. This compares to earnings of $0.87 per share a year ago.
View source ↗ - Newsbusinesswire.com·13d ago·Neutral
Novanta Announces Financial Results for the Third Quarter 2026 BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the third quarter 2026. Financial Highlights Three Months Ended (In millions, except per share amounts) October 2, September 26, 2026 2025 GAAP Revenue $ 305.0 $ 247.8 Operating Income $ 13.9 …
View source ↗ - Newsbusinesswire.com·33d ago·Neutral
Novanta to Present at the Baird 2026 Global Industrial Conference on Wednesday, November 11, 2026 BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, and John Lesica, Chief Operating Officer of Medical Solutions, are scheduled to present at the Baird 2026 Global Industrial Conference on Wednesday, November 11, 2026, in Chicago, I…
View source ↗ - News (RSS)financialpost·40d ago·Neutral
Novanta Inc. Announces Schedule of Third Quarter 2026 Earnings Release and Conference Call BOSTON — Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its third quarter 2026 results after the close of U.S. financial markets on Monday, November 9, 2026. The Company will host a conference call on Tuesday, November 10, 2026 at 8:00 a.m. ET to […]
View source ↗ - Newsbusinesswire.com·40d ago·Neutral
Novanta Inc. Announces Schedule of Third Quarter 2026 Earnings Release and Conference Call BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its third quarter 2026 results after the close of U.S. financial markets on Monday, November 9, 2026. The Company will host a conference call on Tuesday, November 10, 2026 at 8:00 a.m. ET to discuss these results. To access the call, ple…
View source ↗ - Newsetftrends.com·67d ago·Negative
How to Build a Humanoid Body Last month we broke down the three key areas needed to build your own humanoid. We have already looked at the companies behind the technologies required to build a humanoid's brain.
View source ↗ - News (RSS)financialpost·86d ago·Neutral
Novanta to Present at Baird Global Healthcare Conference on Tuesday, September 15, 2026 BOSTON — Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, and John Lesica, Chief Operating Officer of Medical Solutions, are scheduled to present at the Baird Global Healthcare Conference on Tuesday, September 15, 2026, in New York, NY. […]
View source ↗ - Newsbusinesswire.com·86d ago·Neutral
Novanta to Present at Baird Global Healthcare Conference on Tuesday, September 15, 2026 BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, and John Lesica, Chief Operating Officer of Medical Solutions, are scheduled to present at the Baird Global Healthcare Conference on Tuesday, September 15, 2026, in New York, NY. About Novant…
View source ↗ - News (RSS)seekingalpha·91d ago·Positive
Novanta: A Strong Year So Far, Fully Priced In
View source ↗ - News (Marketaux)seekingalpha.com·91d ago·Positive
Novanta: A Strong Year So Far, Fully Priced In (NASDAQ:NOVT) Novanta: A Strong Year So Far, Fully Priced In (NASDAQ:NOVT)
View source ↗ - Newszacks.com·96d ago·Positive
Recent Price Trend in Novanta (NOVT) is Your Friend, Here's Why If you are looking for stocks that are well positioned to maintain their recent uptrend, Novanta (NOVT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
View source ↗ - Newszacks.com·102d ago·Neutral
Are You Looking for a Top Momentum Pick? Why Novanta (NOVT) is a Great Choice Does Novanta (NOVT) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗ - 4chan /biz/biz·104d ago·Negative
>>62579859 kek it’s really hard to see one of your closest allies shooting themselves in the foot, knowing you’ll be blamed for it a month later… >>62579347 yeah we’ll play find 10 differences between sand monkeys later today, thanks for the great idea idk I’ve purposely been avoiding tech this past year like a chick with stds but NOVT and MOG-A look pretty solid and actuators make up for 50+% of the current robotics costs. Anyone knows any good EU defence contractors? Would be really nice know
View source ↗
Earnings
Mon, Feb 22(in 3 months)
Consensus estimate $0.92 per share
Typical surprise +7.2% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 9$1.05 vs $0.97beat
- Wed, Aug 5$0.89 vs $0.83beat
- Mon, May 11$0.81 vs $0.78beat
- Mon, Feb 23$0.91 vs $0.88beat
- Mon, Nov 3$0.87 vs $0.81beat
- Tue, Aug 5$0.76 vs $0.74beat
Estimates and results for NOVT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NOVT officers and directors.
- Bought
- —
- Sold
- $10.5m
0 trades
41 trades
- Secor Thomas Nsold
- Glastra Matthijssold
- Glastra Matthijssold
- Glastra Matthijssold
- Glastra Matthijssold
- Glastra Matthijssold
- Glastra Matthijssold
- Glastra Matthijssold
59 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Cisneroshouse · CA31 · disclosed Jun 9, 2026 (22d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Dec 15, 2025 (32d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Sep 15, 2025 (42d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (22d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Aug 29, 2022 (35d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA39 · disclosed Nov 15, 2019 (24d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA39 · disclosed Aug 19, 2019 (18d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA39 · disclosed Jun 18, 2019 (27d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed May 20, 2019 (35d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA39 · disclosed May 14, 2019 (27d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
